Literature DB >> 24356578

Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction.

Bin Chen1, Li-Yun Zhong, Jin-Xiu Yang, Yan-Yun Pan, Fei Chen, Jian Yang, Tao Wu, Shen-Jiang Hu.   

Abstract

BACKGROUND: Abnormalities of the mevalonate pathway, an important cellular metabolic pathway, are common in many diseases including cardiovascular disease. The mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated diastolic dysfunction remains largely unknown. This study aims to investigate whether the expression of mevalonate pathway related enzyme is altered during the progression of cardiac hypertrophy and associated diastolic dysfunction induced by pressure overload.
METHODS: Male Sprague-Dawley (SD) rats were randomly divided into two groups: the suprarenal abdominal aortic coarctation (AAC) group and the sham group.
RESULTS: Histological and echocardiographic assessments showed that there was a significant cardiovascular remodeling in the AAC group compared with the sham group after 3 weeks post-operatively, and the left ventricular (LV) diastolic function was reduced at 8 and 14 weeks post-operatively in the AAC group, without any change in systolic function during the study. The tissue of the heart and the abdominal aorta proximal to the coarctation showed over-expression of several enzymes, including 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), farnesyl diphosphate synthase (FDPS), farnesyltransferase-α (FNTA), farnesyltransferase-β (FNTB), geranylgeranyltransferase type I (GGTase-I) and the activation of their downstream proteins was enhanced.
CONCLUSIONS: AAC induced compensatory LV hypertrophy to decompensatory diastolic dysfunction, accompanied by altered expression of several key enzymes in the mevalonate pathway.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24356578     DOI: 10.1159/000356610

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  5 in total

1.  Inhibition of farnesyl pyrophosphate synthase improves pressure overload induced chronic cardiac remodeling.

Authors:  Chen-Ze Zhao; Xu-Ming Zhao; Jian Yang; Yun Mou; Bin Chen; Huan-Dong Wu; Dong-Pu Dai; Jie Ding; Shen-Jiang Hu
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

2.  Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes.

Authors:  Jie Ding; Yu X Chen; Yan Chen; Yun Mou; Xiao T Sun; Dong P Dai; Chen Z Zhao; Jian Yang; Shen J Hu; Xiaogang Guo
Journal:  J Cell Mol Med       Date:  2020-06-24       Impact factor: 5.310

3.  Inhibition of the mevalonate pathway improves myocardial fibrosis.

Authors:  Huifeng Xu; Yi Shen; Chenyu Liang; Haifeng Wang; Junling Huang; Pengcheng Xue; Ming Luo
Journal:  Exp Ther Med       Date:  2021-01-18       Impact factor: 2.447

4.  A Mathematical Model of In Vitro Cellular Uptake of Zoledronic Acid and Isopentenyl Pyrophosphate Accumulation.

Authors:  Elena Lo Presti; Laura D'Orsi; Andrea De Gaetano
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

5.  Geranylgeranyl Transferase-I Knockout Inhibits Oxidative Injury of Vascular Smooth Muscle Cells and Attenuates Diabetes-Accelerated Atherosclerosis.

Authors:  Guo-Ping Chen; Jian Yang; Guo-Feng Qian; Wei-Wei Xu; Xiao-Qin Zhang
Journal:  J Diabetes Res       Date:  2020-08-10       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.